Anders G Olsson

Summary

Country: Sweden

Publications

  1. ncbi request reprint Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
    Anders G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Am Heart J 144:1044-51. 2002
  2. ncbi request reprint Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits
    Wei Li
    Division of Pathology II, Faculty of Health Sciences, Linkoping University, SE 581 85 Linkoping, Sweden
    J Mol Cell Cardiol 37:969-78. 2004
  3. ncbi request reprint Lipid lowering and aortic valve disease
    Anders G Olsson
    Faculty of Health Sciences, Linkoping University, Bromma, Sweden
    Curr Atheroscler Rep 11:377-83. 2009
  4. ncbi request reprint High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
    Anders G Olsson
    Department of Medicine and Care, Internal Medicine, University of Linkoping, SE 58185 Linkoping, Sweden
    Eur Heart J 26:890-6. 2005
  5. ncbi request reprint [Apolipoprotein A-I can be a new tool in the treatment of atherosclerosis]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet och EM kliniken, Universitetssjukhuset i Linköping
    Lakartidningen 101:1196-7. 2004
  6. ncbi request reprint [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet, Universitetssjukhuset, Linkoping
    Lakartidningen 103:22-3. 2006
  7. ncbi request reprint Psychosocial factors and coronary heart disease
    Anders G Olsson
    Department of Medicine and Care, Faculty of Health Sciences, University Hospital, SE 58185 Linkoping, Sweden
    Curr Atheroscler Rep 6:1-2. 2004
  8. ncbi request reprint Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data
    Anders G Olsson
    Department of Medicine and Care, University Hospital, S 581 85 Linkoping, Sweden
    Curr Atheroscler Rep 8:382-9. 2006
  9. ncbi request reprint [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet, Universitetssjukhuset, Linkoping
    Lakartidningen 103:2454-5. 2006
  10. ncbi request reprint Expanding options with a wider range of rosuvastatin doses
    Anders G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Clin Ther 28:1747-63. 2006

Detail Information

Publications49

  1. ncbi request reprint Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
    Anders G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Am Heart J 144:1044-51. 2002
    ..We compared the effects of rosuvastatin and atorvastatin in reducing LDL-C and achieving LDL-C goals in patients with primary hypercholesterolemia...
  2. ncbi request reprint Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits
    Wei Li
    Division of Pathology II, Faculty of Health Sciences, Linkoping University, SE 581 85 Linkoping, Sweden
    J Mol Cell Cardiol 37:969-78. 2004
    ..Apoptosis reduction by alpha-tocopherol and astaxanthin may be a new anti-atherogenic property of these antioxidants...
  3. ncbi request reprint Lipid lowering and aortic valve disease
    Anders G Olsson
    Faculty of Health Sciences, Linkoping University, Bromma, Sweden
    Curr Atheroscler Rep 11:377-83. 2009
    ..The outcome of the ongoing Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) study, which is examining lipid lowering as a treatment for AS, is greatly anticipated...
  4. ncbi request reprint High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
    Anders G Olsson
    Department of Medicine and Care, Internal Medicine, University of Linkoping, SE 58185 Linkoping, Sweden
    Eur Heart J 26:890-6. 2005
    ..We determined whether plasma lipoproteins at baseline and then at 6 weeks after randomization predicted clinical outcome...
  5. ncbi request reprint [Apolipoprotein A-I can be a new tool in the treatment of atherosclerosis]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet och EM kliniken, Universitetssjukhuset i Linköping
    Lakartidningen 101:1196-7. 2004
    ..Large-scale efficacy and safety studies will be necessary in order to establish apolipoprotein A-I as the next tool to fight coronary heart disease. The study is in line with the cholesterol hypothesis...
  6. ncbi request reprint [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet, Universitetssjukhuset, Linkoping
    Lakartidningen 103:22-3. 2006
  7. ncbi request reprint Psychosocial factors and coronary heart disease
    Anders G Olsson
    Department of Medicine and Care, Faculty of Health Sciences, University Hospital, SE 58185 Linkoping, Sweden
    Curr Atheroscler Rep 6:1-2. 2004
  8. ncbi request reprint Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data
    Anders G Olsson
    Department of Medicine and Care, University Hospital, S 581 85 Linkoping, Sweden
    Curr Atheroscler Rep 8:382-9. 2006
    ..This review examines recent data highlighting the benefits of more pronounced LDL cholesterol reductions and considers how this could be achieved in clinical practice when many patients are not even reaching current targets...
  9. ncbi request reprint [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet, Universitetssjukhuset, Linkoping
    Lakartidningen 103:2454-5. 2006
  10. ncbi request reprint Expanding options with a wider range of rosuvastatin doses
    Anders G Olsson
    Department of Medicine and Care, University Hospital, Linkoping, Sweden
    Clin Ther 28:1747-63. 2006
    ..The dose range for rosuvastatin in Europe has recently been expanded to 5 to 40 mg and is now in line with the dose range currently available in the United States...
  11. ncbi request reprint Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    Am J Cardiol 99:632-5. 2007
    ..In conclusion, these results and a greater immediate cardiovascular risk in older patients argue for early, intensive atorvastatin therapy as routine practice after ACS...
  12. ncbi request reprint Will CETP inhibition survive the demise of torcetrapib?
    Anders G Olsson
    Faculty of Health Sciences, Linköping University and Stockholm Heart Center, Bergviksvägen 48, SE 167 63 Bromma, Sweden
    Curr Atheroscler Rep 10:97-9. 2008
  13. ncbi request reprint [National guidelines for cardiology 2008: Description of the status or an instrument for change?]
    Anders G Olsson
    Hälsouniversitet, Linkoping
    Lakartidningen 105:1308-9. 2008
  14. doi request reprint Is high HDL cholesterol always good?
    Anders G Olsson
    Department of Medicine and Health, Faculty of Health Sciences, University of Linkoping, Sweden
    Ann Med 41:11-8. 2009
    ..New interventional studies on this therapeutic principle are welcomed and under way...
  15. ncbi request reprint [The TNT debate gives a lift to the debate about high-dose statins. Lower LDL cholesterol levels further reduce the cardiovascular risk]
    Anders G Olsson
    Institutionen för medicin och vård, Internmedicin, Berzelius Science Park, Universitets sjukhuset, Linkoping
    Lakartidningen 102:1393-4. 2005
  16. ncbi request reprint Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial
    Bengt Fellstrom
    Department of Medical Science, Renal Science, Renal Unit, University Hospital, Uppsala, Sweden
    Transplantation 79:205-12. 2005
    ....
  17. doi request reprint LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
    Anders G Olsson
    Department of Internal Medicine, University Hospital, Linkoping, Sweden
    Eur J Cardiovasc Prev Rehabil 18:262-9. 2011
    ..5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups...
  18. ncbi request reprint A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study
    Anders G Olsson
    Department of Medicine and Care, University Hospital of Linkoping, Linkoping, Germany
    Clin Ther 25:119-38. 2003
    ..Guidelines for the prevention of coronary heart disease call for low-density lipoprotein cholesterol (LDL-C) reduction as the primary target of treatment and reduction of triglycerides (TG) as an additional target...
  19. ncbi request reprint Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia
    Gunilla Hollman
    Division of Nursing Science, Department of Medicine and Care, Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    J Cardiovasc Nurs 21:103-8. 2006
    ..Knowledge about the condition and adherence to drug treatment may facilitate reaching treatment goals...
  20. ncbi request reprint The role of statins in the prevention of ischemic stroke
    Bo Ziedén
    Department of Medicine and Care, Faculty of Health Sciences, University Hospital, SE 58185 Linkoping, Sweden
    Curr Atheroscler Rep 7:364-8. 2005
    ....
  21. ncbi request reprint Early initiation of treatment with statins in acute coronary syndromes
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Sweden
    Ann Med 34:37-41. 2002
    ..The studies highlight the importance of treatment with a statin in the early management of acute coronary syndromes and the need to incorporate this therapeutic strategy in national guidelines and treatment recommendations...
  22. ncbi request reprint Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor
    Anders G Olsson
    University Hospital, Linkoping, Sweden
    Cardiovasc Drug Rev 20:303-28. 2002
    ..A large, long-term clinical trials program is under way to investigate the effects of rosuvastatin on atherosclerosis and cardiovascular morbidity and mortality...
  23. doi request reprint Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
    Anders G Olsson
    Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
    Expert Opin Pharmacother 11:1715-26. 2010
    ..In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density lipoprotein (LDL)-cholesterol and lipoprotein(a) and has been named the broad-spectrum lipid drug...
  24. ncbi request reprint [New discoveries are against statin treatment of acute coronary disease. But the assessment of therapeutic effects based on observational studies is difficult]
    Anders G Olsson
    Institutionen för medicin och vård, Hälsouniversitetet, Linkoping
    Lakartidningen 99:4348-9. 2002
  25. ncbi request reprint Meaning of quality of life among patients with familial hypercholesterolemia
    Gunilla Hollman
    Department of Medicine and Care, Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    J Cardiovasc Nurs 19:243-50. 2004
    ..Living with a genetic predisposition to disease may influence quality of life. The presence of premature disease can lead to an increased focus on family history and genetic predisposition...
  26. ncbi request reprint Good self-rated health is related to psychosocial resources and a strong cortisol response to acute stress: the LiVicordia study of middle-aged men
    Margareta Kristenson
    Department of Health and Society, Faculty of Health Sciences, Linkping University, Sweden
    Int J Behav Med 12:153-60. 2005
    ..27, p = .001). Findings that good SRH related to favorable psychosocial characteristics and to a dynamic cortisol stress response indicate a possible explanation for observed lower risk for disease and death in this state...
  27. ncbi request reprint Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
    Bengt Fellstrom
    University Hospital, Uppsala, Sweden
    Kidney Int 66:1549-55. 2004
    ..The aim of the present study was to evaluate the effect of fluvastatin on long-term renal transplant function and development of chronic allograft nephropathy in the ALERT (Assessment of Lescol in Renal Transplantation) study...
  28. ncbi request reprint Effects of alpha-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits
    Leif S Jacobsson
    Department of Pharmacology, Faculty of Health Sciences, Linkoping University, Linkoping SE 581 85, Sweden
    Atherosclerosis 173:231-7. 2004
    ..It can be concluded that alpha-tocopherol but not astaxanthin prolonged the LDL oxidation lag time. The two antioxidative substances did not prevent atherogenesis in WHHL rabbits in this setting...
  29. ncbi request reprint Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
    Peter Lindgren
    European Health Economics, Vasagatan 38, 111 20 Stockholm, Sweden
    Eur Heart J 28:1448-53. 2007
    ....
  30. ncbi request reprint Effects of astaxanthin supplementation on lipid peroxidation
    Jouni Karppi
    Research Institute of Public Health, University of Kuopio, P O Box 1627, FI 70211 Kuopio, Finland
    Int J Vitam Nutr Res 77:3-11. 2007
    ..The present study suggests that intestinal absorption of astaxanthin delivered as capsules is adequate, and well tolerated. Supplementation with astaxanthin may decrease in vivo oxidation of fatty acids in healthy men...
  31. ncbi request reprint Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Veterans Affairs Boston Healthcare System, West Roxbury, Mass, USA
    Arterioscler Thromb Vasc Biol 28:142-7. 2008
    ..We measured markers of inflammation in the MIRACL study, a randomized trial of atorvastatin versus placebo in acute coronary syndromes, to assess the relationship of inflammation to stroke...
  32. doi request reprint High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies
    Wim A van der Steeg
    Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    J Am Coll Cardiol 51:634-42. 2008
    ....
  33. ncbi request reprint Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco School of Medicine, San Francisco, Calif 94110, USA
    Circulation 106:1690-5. 2002
    ..4% in the placebo group to 14.8% in the atorvastatin group over the 16 weeks of the trial (P=0.048)...
  34. ncbi request reprint Lipid lowering in acute coronary syndromes: new evidence, new questions
    Gregory G Schwartz
    Cardiology Section, 111B, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Curr Atheroscler Rep 4:1-3. 2002
  35. ncbi request reprint Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    Hallvard Holdaas
    Lancet 361:2024-31. 2003
    ..We investigated the effects of fluvastatin on cardiac and renal endpoints in this population...
  36. ncbi request reprint High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1560-6. 2003
    ..Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown...
  37. ncbi request reprint High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
    Sotirios Tsimikas
    Vascular Medicine Program, Department of Medicine, University of California San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093 0682, USA
    Circulation 110:1406-12. 2004
    ..This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS)...
  38. ncbi request reprint [The lower LDL cholesterol the better!]
    Ulf Stenestrand
    Kardiologiska kliniken, Universitetssjukhuset i Linköping
    Lakartidningen 101:3246-7. 2004
  39. ncbi request reprint Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease
    Johnny Nijm
    Research Center of Cardiovascular Disease, Högland Hospital, Eksjo, Sweden
    Am J Cardiol 95:452-6. 2005
    ..The data suggest that the interaction between neutrophils and platelets is an important component of proinflammatory activity seen in peripheral blood of stable and unstable forms of coronary artery disease...
  40. ncbi request reprint Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 110:386-91. 2004
    ..Statins inhibit CD40L signaling in vitro, but there are no prospective studies of statins and sCD40L in acute coronary syndromes...
  41. ncbi request reprint fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study
    Alan G Jardine
    Western Infirmary, Glasgow, Scotland, UK
    Am J Transplant 4:988-95. 2004
    ..The subgroups included patients at lower cardiovascular risk, who were younger, nondiabetic, nonsmokers and without pre-existing CVD. These data support the early introduction of statins following renal transplantation...
  42. ncbi request reprint Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study
    Alan G Jardine
    University of Glasgow, UK
    Am J Kidney Dis 46:529-36. 2005
    ..We analyzed the data in the placebo arm of Assessment of Lescol in Renal Transplantation (ALERT) to improve our understanding of the relationship between cardiovascular risk factors and outcomes in this unique population...
  43. ncbi request reprint Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
    Gregory G Schwartz
    Cardiology Section, VA Medical Center, Denver, Colorado 80220, USA
    Diabetes Care 28:2508-13. 2005
    ..We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy after acute coronary syndrome...
  44. ncbi request reprint High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    Terje R Pedersen
    Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
    JAMA 294:2437-45. 2005
    ..Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease...
  45. ncbi request reprint Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
    Terje R Pedersen
    Center for Preventive Medicine, Ulleval University Hospital, N 0407 Oslo, Norway
    Am J Cardiol 94:720-4. 2004
    ..2 +/- 0.3 mmol/L (46 mg/dl). Drug treatment before randomization consisted of statins in 77% of patients, aspirin in 78.9%, beta blockers in 75.1%, and angiotensin-converting enzyme inhibitors in 30%...
  46. doi request reprint Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    John J P Kastelein
    Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Circulation 117:3002-9. 2008
    ....
  47. ncbi request reprint The case for intensive statin therapy after acute coronary syndromes
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Am J Cardiol 96:45F-53F. 2005
    ..Moreover, evidence suggests that anti-inflammatory effects of high-intensity statin treatment are associated with clinical benefit...
  48. doi request reprint NICE lipid modification guideline: both absolute and obsolete!
    Anders G Olsson
    Heart 94:1256-7. 2008
  49. ncbi request reprint Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998
    Terje R Pedersen
    Atheroscler Suppl 5:99-106. 2004